Knowledge Tree
Parkinson's disease
Also known as: Parkinson's, Parkinson disease, PD
Facts (66)
Sources
Extent and Health Consequences of Chronic Sleep Loss and ... - NCBI ncbi.nlm.nih.gov 42 facts
claimIndividuals with dementia, including Alzheimer’s disease, Parkinson’s disease, dementia with Lewy bodies, Huntington’s disease, and Creutzfeldt-Jakob disease, commonly experience sleep abnormalities.
measurementThe EUROPARKINSON Collaborative Study, involving researchers including de Rijk MC and Tzourio C, estimated the prevalence of parkinsonism and Parkinson’s disease in Europe.
claimMany individuals with Parkinson’s disease experience excessive daytime sleepiness.
claimDopamine agonists are associated with sleep attacks and daytime sleepiness in patients with Parkinson’s disease, as reported in a 2003 study in Movement Disorders.
referenceBraak H, Ghebremedhin E, Rub U, Bratzke H, and Del Tredici K published a study titled 'Stages in the development of Parkinson’s disease-related pathology' in Cell and Tissue Research in 2004 (Volume 318, Issue 1, pages 121–134).
referenceJellinger K authored a chapter on the pathology of Parkinsonism in the 1986 book 'Recent Developments in Parkinson’s Disease'.
claimParkinson’s disease is a neurological disorder characterized by trouble initiating walking and other movements, muscle tremor, a slow gait, and reduced facial expressions.
claimNeurodegeneration in Parkinson's disease involves a reduction in the number of dopaminergic neurons in the substantia nigra, noradrenergic neurons in the locus coeruleus, and cholinergic neurons in the pedunculopontine nucleus.
measurementThe EUROPARKINSON Collaborative Study estimated the prevalence of parkinsonism and Parkinson’s disease across Europe.
claimSecondary cases of narcolepsy or hypersomnia can occur in the context of psychiatric disorders (e.g., depression), central nervous system tumors (notably in the hypothalamus), neurodegenerative disorders (e.g., Parkinson’s disease), inflammatory disorders (e.g., multiple sclerosis or paraneoplastic syndromes), traumatic disorders (e.g., head trauma), vascular disorders (e.g., median thalamic stroke), and genetic disorders (e.g., myotonic dystrophy or Prader-Willi syndrome).
referenceCantor CR and Stern MB reviewed the effects of dopamine agonists on sleep in patients with Parkinson’s disease, published in Neurology in 2002.
referenceGagnon JF et al. published research in Neurology in 2002 identifying REM sleep behavior disorder and REM sleep without atonia in patients with Parkinson’s disease.
referenceBergonzi et al. (1975) studied sleep organization in patients with Parkinson’s syndrome before and after treatment with L-dopa combined with a dopa-decarboxylase inhibitor.
claimExcessive daytime sleepiness, including sleep attacks, has been associated with the use of dopamine agonists in Parkinson’s disease patients (Paus et al., 2003).
referenceChrisp, Mammen, and Sorkin (1991) reviewed the pharmacology, symptomatic benefits, and protective potential of selegiline in the treatment of Parkinson’s disease.
claimBraak and colleagues (2004) found that Lewy body degeneration begins in the lower brainstem and ascends to involve the substantia nigra only after several years, which is consistent with observations that REM sleep alterations may precede movement disorders by several years in many Parkinson’s disease patients.
claimParkinson’s disease is commonly treated with dopamine precursors (levodopa/carbidopa) and dopamine agonists (pramipexole and ropinirole).
claimLow doses of dopaminergic medications can promote sleep in Parkinson's disease patients, whereas high doses may cause increased nocturnal wakefulness, decreased slow-wave sleep (SWS), and decreased sleep continuity.
referenceComella et al. (1998) investigated the relationship between sleep-related violence, injury, and REM sleep behavior disorder in patients with Parkinson’s disease.
claimREM sleep behavioral disorder is frequently observed in patients with Parkinson’s disease and other parkinsonian syndromes, such as multiple systems atrophy and progressive supranuclear palsy.
measurementSleep disturbances in Parkinson’s disease patients typically increase with disease progression, with individuals spending as much as 30 to 40 percent of the night awake due to increased sleep latency and frequent awakenings, as reported by Kales et al. (1971) and Bergonzi et al. (1975).
claimIn Parkinson's disease, dopaminergic neurons in the substantia nigra are dramatically reduced in number, as are noradrenergic neurons in the locus coeruleus (Jellinger, 1986) and cholinergic neurons in the pedunculopontine nucleus (Zweig et al., 1989).
referenceA 1991 review published in Drugs and Aging examined the pharmacology, symptomatic benefits, and protective potential of selegiline in the treatment of Parkinson’s disease.
claimMany patients with Parkinson’s disease require daytime stimulants, such as modafinil or amphetamine, to relieve excessive sleepiness.
claimExcessive daytime sleepiness, including sleep attacks, has been associated with the use of dopamine agonists in patients with Parkinson’s disease, often requiring the use of daytime stimulants such as modafinil or amphetamine to relieve the sleepiness.
referenceA 1998 study published in Neurology found links between sleep-related violence, injury, and REM sleep behavior disorder in patients with Parkinson’s disease.
measurementThe prevalence of Parkinson’s disease ranges from 0.9 percent of people aged 65 to 69 years to upwards of 5 percent of people aged 80 to 84 years.
measurementAt least 15 percent of individuals with Parkinson’s disease suffer from REM sleep behavior disorder.
referenceLeeman AL, O'Neill CJ, Nicholson PW, Deshmukh AA, Denham MJ, Royston JP, Dobbs RJ, and Dobbs SM studied the response to and optimal spacing of nighttime levodopa dosing for Parkinson’s disease in the elderly in a 1987 study published in the British Journal of Clinical Pharmacology.
referenceKaakkola S reviewed the clinical pharmacology, therapeutic use, and potential of COMT inhibitors in Parkinson’s disease in a 2000 article in Drugs.
measurementParkinson’s disease affects 0.9 percent of people aged 65 to 69 years and up to 5 percent of people aged 80 to 84 years.
claimLeeman AL et al. studied the response to and optimal spacing of night time dosing with levodopa for Parkinson’s disease in the elderly in 1987.
claimParkinson’s disease is commonly treated with dopamine precursors such as levodopa/carbidopa and dopamine agonists such as pramipexole and ropinirole.
claimMedications used to treat Parkinson’s disease include monoamine oxidase-B inhibitors (selegiline), presynaptic releasing agents (amantadine, anticholinergic agents), and catechol-O-methyltransferase (COMT) inhibitors (hyoscyamine, benztropine), all of which may potentially affect sleep (Chrisp et al., 1991).
claimIndividuals with Parkinson’s disease often experience excessive daytime sleepiness, and sleep disturbances typically increase as the disease progresses.
measurementIndividuals with Parkinson’s disease suffer from increased sleep latency and frequent awakenings, spending as much as 30 to 40 percent of the night awake.
claimTreating sleep disturbances in Parkinson’s disease is complicated by the varying actions of dopaminergic medications.
claimMedications used to treat Parkinson’s disease, specifically dopamine precursors like levodopa/carbidopa and dopamine agonists like pramipexole and ropinirole, can promote sleep when used in low doses, but high doses may cause increased nocturnal wakefulness, decreased slow-wave sleep (SWS), and decreased sleep continuity (Leeman et al., 1987; Monti et al., 1988; Cantor and Stern, 2002).
claimSleep disturbances in Parkinson’s disease typically increase as the disease progresses.
claimSleep disturbances associated with Parkinson’s disease include difficulty falling asleep, nocturnal akinesia, altered sleep architecture, abnormal motor activity, periodic limb movements, REM sleep behavior disorder, and disturbed breathing.
referenceKales A et al. studied sleep in patients with Parkinson’s disease and normal subjects before and after levodopa administration, published in Clinical Pharmacology and Therapeutics in 1971.
referenceZweig RM, Jankel WR, Hedreen JC, Mayeux R, and Price DL authored 'The pedunculopontine nucleus in Parkinson’s disease,' published in the Annals of Neurology in 1989.
Medicinal plants and human health: a comprehensive review of ... link.springer.com Nov 5, 2025 5 facts
claimChemicals including baicalein, catechins, and nordihydroguaiaretic acid obstruct the transformation of α-synuclein from its native conformation to pathological aggregates, inhibiting the development of Lewy bodies associated with Parkinson’s disease.
claimBaicalein from Scutellaria baicalensis, morin from mulberry, and myricetin from berries and grapes inhibit α-synuclein aggregation linked to Parkinson’s disease, providing neuroprotective advantages.
claimCatechins derived from green tea, specifically epicatechin gallate, exhibit anti-aggregation properties in cellular and animal models of Parkinson’s disease.
referenceCurcumin is associated with aging and age-related neurodegenerative diseases, specifically Alzheimer's and Parkinson's disease, as reviewed by Turer and Sanlier in their 2025 narrative review.
referenceAnjum (2025) published a comprehensive preclinical review in Pharmacological Research-Modern Chinese Medicine regarding the neuroprotective role of traditional Chinese plant extracts in treating Parkinson's disease.
Why Sleep Is Important for Brain Health - American Brain Foundation americanbrainfoundation.org Mar 16, 2022 5 facts
claimREM sleep behavior disorder (RBD) can be considered a prodromal syndrome, or a sign that may precede Parkinson’s disease, and individuals with RBD are more likely to develop cognitive problems or dementia.
claimSleep disturbances are correlated with numerous neurological diseases, including stroke, cognitive aging, dementia, and Parkinson’s disease.
claimMany people with Parkinson’s disease experience REM sleep behavior disorder (RBD), where they physically act out their dreams, for years before receiving a Parkinson's diagnosis.
claimSleep and circadian rhythm dysfunction, such as fragmented sleep or night wakings, may be a risk factor for neurodegenerative disorders like Alzheimer’s and Parkinson’s disease.
claimIn a study of individuals with Parkinson’s disease, timed light therapy improved daytime sleepiness, sleep quality, daily physical activity levels, and the Total Unified Parkinson’s Disease Rating Scale score.
Sleep Deprivation: What It Is, Symptoms, Treatment & Stages my.clevelandclinic.org Aug 11, 2022 2 facts
claimMedical causes of sleep deprivation include sleep apnea, degenerative brain disorders (such as Alzheimer’s disease or Parkinson’s disease), mental health concerns, concussions, traumatic brain injuries, pain, insomnia, and restless leg syndrome.
claimSleep deprivation can be caused by medical reasons including sleep apnea, degenerative brain disorders (such as Alzheimer’s disease or Parkinson’s disease), mental health concerns, concussions, traumatic brain injuries, pain, insomnia, and restless leg syndrome.
U shaped association between sleep duration and long ... nature.com by F Feng · 2025 2 facts
referenceREM sleep behavior disorder is associated with cognitive dysfunctions in Parkinson’s disease, as determined by a systematic review and meta-analysis conducted by Mao et al. (2020).
claimREM sleep behavior disorder (RBD) is associated with synucleinopathies like Parkinson’s disease and dementia with Lewy bodies, and often presents with extended sleep duration as patients attempt to compensate for disrupted sleep architecture.
Physiology, Sleep Stages - StatPearls - NCBI Bookshelf - NIH ncbi.nlm.nih.gov 2 facts
claimREM sleep behavior disorder may be associated with degenerative neurological conditions such as Parkinson disease or Lewy body dementia, and has been shown to be caused by antidepressant use.
referenceBugalho P and Magriço M published a study in 2022 in 'Acta Neurologica Scandinavica' regarding sleep stability in patients with isolated rapid eye movement sleep behavior disorder, Parkinson's disease, and dementia with Lewy bodies.
Bridging the Gap Between LLMs and Evolving Medical Knowledge arxiv.org Jun 29, 2025 1 fact
measurementThe relationship between Levodopa and Parkinson’s disease in the Medical Knowledge Graph (MKG) received a reliability rating of 9.6/10 from LLM analysis and 10/10 from medical expert analysis, and it increases query accuracy by 24% regarding Parkinson’s treatments and comorbidities.
What Is Inflammation? Types, Causes & Treatment my.clevelandclinic.org Mar 22, 2024 1 fact
claimChronic inflammation is involved in the disease process of autoimmune diseases (lupus, rheumatoid arthritis, psoriasis, ankylosing spondylitis), cardiovascular diseases (heart disease, high blood pressure), certain cancers, gastrointestinal diseases (Crohn’s disease, inflammatory bowel disease), lung diseases (asthma, chronic obstructive pulmonary disease), mental health conditions (depression, anxiety), metabolic diseases (Type 2 diabetes), and neurodegenerative diseases (Alzheimer’s disease, Parkinson’s disease).
A Double-Edged Sword: Inflammation and Your Health - Cedars-Sinai cedars-sinai.org Feb 12, 2021 1 fact
claimMicroglia cells in the brain react when the brain is confronted with conditions such as Parkinson’s disease, Alzheimer’s disease, or infections like COVID-19 that introduce inflammatory proteins into the blood.
Impact of sleep duration on executive function and brain structure nature.com Mar 3, 2022 1 fact
procedureThe researchers excluded individuals from the study who had a history or current diagnosis of neurological disease, stroke, transient ischaemic attack, brain injury, subdural or subarachnoid haematoma, infection of the nervous system, brain abscess, haemorrhage, skull fracture, encephalitis, meningitis, chronic neurological problems, amyotrophic lateral sclerosis, multiple sclerosis, Parkinson’s disease, Alzheimer’s disease, epilepsy, head injury, or alcohol, opioid, and other dependencies.
Effects of psychedelics on neurogenesis and broader neuroplasticity link.springer.com Dec 19, 2024 1 fact
claimAyahuasca demonstrates neuroprotective potential and has been analyzed via untargeted metabolomics for its applicability to Parkinson’s disease.
Inflammation: Definition, Diseases, Types, and Treatment - WebMD webmd.com Jul 14, 2024 1 fact
claimInflammatory conditions include neurological conditions (Alzheimer’s disease, Parkinson's), autoimmune disorders (rheumatoid arthritis, lupus, psoriasis), gastrointestinal conditions (Crohn's disease, irritable bowel syndrome, ulcerative colitis), mental health disorders (depression, anxiety), cardiovascular issues (high blood pressure, heart disease), lung disease (asthma, COPD), metabolic disorders (type 2 diabetes), and certain cancers.
the consumption of psychoactive plants in ancient global and ... academia.edu 1 fact
referenceChagas MH et al. published 'Cannabidiol can improve complex sleep-related behaviors associated with REM sleep behavior disorder in Parkinson's disease patients: a case series' in the Journal of Clinical Pharmacy & Therapeutics in 2014.
Chronic Inflammation: How to Test For it and Prevent it medichecks.com Jan 31, 2024 1 fact
claimChronic inflammation is associated with various conditions, including autoimmune diseases (thyroid conditions, rheumatoid arthritis), cardiovascular diseases (high blood pressure, heart disease), gastrointestinal disorders (inflammatory bowel disease, Crohn's disease, ulcerative colitis), lung diseases (COPD, asthma), mood conditions (depression), metabolic diseases (type 2 diabetes), neurodegenerative diseases (Parkinson’s disease), and some cancers.